Vertex Pharmaceuticals Inc. (VRTX) announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have one F508del mutation and one minimal function mutation.
from RTT - Before the Bell http://ift.tt/2uC7pgh
via IFTTT
No comments:
Post a Comment